Geburtshilfe Frauenheilkd 2016; 76 - P373
DOI: 10.1055/s-0036-1592839

Paget's disease of the vulva treated with imiquimod: case report and review of the literature

A Dogan 1, Z Hilal 1, H Krentel 2, C Cetin 1, L Hefler 3, CB Tempfer 1
  • 1Department of Obstetrics and Gynecology, Ruhr University Bochum, Herne, Deutschland
  • 2Department of Obstetrics and Gynecology, St. Anna Hospital, Herne, Deutschland
  • 3Department of Obstetrics and Gynecology, Krankenhaus der Barmherzigen Schwestern, Linz, Österreich

Background: Extramammary Paget's disease of the vulva (EPDV) is a rare adenocarcinoma in situ of the vulvar skin and is often resected with involved margins due to its reticular growth pattern. Adjuvant treatment with the immunomodulator imiquimod may be suitable to avoid repeated and mutilating surgery.

Case presentation: We present the case of a 73-year-old woman with EPDV, initially treated with surgical resection and re-resection for involved margins. Final histology revealed Paget's disease of the left vulva with 8 cm in the largest diameter and again involved margins. Subsequently, topical therapy with imiquimod 5% cream twice weekly was applied for 3 months. Vulvoscopy and local biopsies confirmed complete remission. Based on a literature search using PubMed and the Cochrane Central Register of Controlled Trials, 21 reports on the therapeutic efficacy of imiquimod in 70 women with EPDV have been published. Pooled rates of complete remission and partial remission were 71% (50/70) and 16% (11/70), respectively. There were 4 cases of disease progression under imiquimod and the therapy was generally well tolerated with mild to moderate local reactions in > 50% of cases.

Conclusion: EPDV is a rare genital neoplasia and may be successfully treated with the topical immunomodulator imiquimod. Specifically, adjuvant imiquimod is a feasible and efficacious treatment option for women with involved resection margins after surgery.